ArmaGen, a private biotech firm, has signed a licensing agreement to fund development of AGT-182, an investigational enzyme to treat degenerative nerve disorder Hunter syndrome.

Under the agreement, Calabasas-based ArmaGen will receive payments up to $225 million, including an initial upfront payment of $15 million in cash and equity, from Shire plc, an Irish pharmaceutical company...

Join our Membership to get the full story.

Are you a current Member? Sign In